Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis

Biological therapies are safer and more effective against psoriasis than conventional treatments. Even so, 30–50% of psoriatic patients show an inadequate response, which is associated with individual genetic heterogeneity. Pharmacogenetic studies have identified several single nucleotide polymorphi...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2024-01, Vol.33 (1), p.e15003-n/a
Main Authors: Loras, Alba, Gil‐Barrachina, Marta, Hernando, Barbara, Perez‐Pastor, Gemma, Martinez‐Domenech, Alvaro, Mahiques, Laura, Pitarch, Gerard, Valcuende‐Cavero, Francisca, Ballester‐Sanchez, Rosa, Marques‐Torrejon, Maria Angeles, Martinez‐Cadenas, Conrado
Format: Article
Language:English
Subjects:
biological drugs
Correlation analysis
Humans
Immune response
Immunity
Immunological diseases
Immunotherapy
Interleukin-12 - genetics
PASI response
Patients
pharmacogenetics
Polymorphism, Single Nucleotide
Psoriasis
Psoriasis - drug therapy
Psoriasis - genetics
psoriasis area severity index
Severity of Illness Index
Single-nucleotide polymorphism
TLR2 protein
TLR5 protein
Toll-like receptors
Treatment Outcome
Tumor Necrosis Factor Inhibitors - therapeutic use
Tumor Necrosis Factor-alpha - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biological therapies are safer and more effective against psoriasis than conventional treatments. Even so, 30–50% of psoriatic patients show an inadequate response, which is associated with individual genetic heterogeneity. Pharmacogenetic studies have identified several single nucleotide polymorphisms (SNPs) as possible predictive and prognostic biomarkers for psoriasis treatment response. The objective of this study was to determine the link between several SNPs and the clinical response to biological therapies in patients with moderate–severe psoriasis. A set of 21 SNPs related to psoriasis and/or other immunological diseases were selected and analysed from salivary samples of patients (n = 88). Treatment effectiveness and patient improvement was assessed clinically through Relative Psoriasis Area and Severity Index (PASI), also called ‘PASI response’, as well as absolute PASI. Associations between SNPs and PASI factors were assessed at 3 and 12 months for every treatment category of IL‐17, IL‐23, IL‐12&23 and TNF‐α inhibitors. Multivariate correlation analysis and Fisher's exact test were used to analyse the relationship between SNPs and therapy outcomes. Several SNPs located in the TLR2, TLR5, TIRAP, HLA‐C, IL12B, SLC12A8, TNFAIP3 and PGLYRP4 genes demonstrated association with increased short and long‐term therapy‐effectiveness rates. Most patients achieved values of PASI response ≥75 or absolute PASI
ISSN:0906-6705
1600-0625
DOI:10.1111/exd.15003